A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Alcaftadine; Dextrans; Olopatadine Hydrochloride

Criteria

Inclusion Criteria:

• History of ocular allergies within the past 24 months.

• Able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period.

Exclusion Criteria:

• Any presence of active ocular infection or history of an ocular herpetic infection.

• Ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months.

• Have any planned surgery during the study or 30 days after the study.